Drug Profile
FT 1518
Alternative Names: FT-1518Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator FTG Bio
- Developer FTG Bio; Vipragen Biociences
- Class Antineoplastics
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Oct 2023 FT 1518 is still in preclinical trials for Cancer in USA
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)